BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21330473)

  • 1. Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.
    Du W; Li XE; Sipple J; Pang Q
    Blood; 2011 Apr; 117(16):4243-52. PubMed ID: 21330473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
    Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.
    Testa U; Riccioni R; Militi S; Coccia E; Stellacci E; Samoggia P; Latagliata R; Mariani G; Rossini A; Battistini A; Lo-Coco F; Peschle C
    Blood; 2002 Oct; 100(8):2980-8. PubMed ID: 12351411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live kinase B1 maintains CD34
    Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
    Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents.
    Ikezoe T; Yang J; Nishioka C; Kojima S; Takeuchi A; Phillip Koeffler H; Yokoyama A
    Int J Cancer; 2011 May; 128(10):2317-25. PubMed ID: 21128225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
    Herrmann H; Kneidinger M; Cerny-Reiterer S; Rülicke T; Willmann M; Gleixner KV; Blatt K; Hörmann G; Peter B; Samorapoompichit P; Pickl W; Bharate GY; Mayerhofer M; Sperr WR; Maeda H; Valent P
    Curr Cancer Drug Targets; 2012 Jan; 12(1):51-63. PubMed ID: 22165967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.
    Jordan CT; Upchurch D; Szilvassy SJ; Guzman ML; Howard DS; Pettigrew AL; Meyerrose T; Rossi R; Grimes B; Rizzieri DA; Luger SM; Phillips GL
    Leukemia; 2000 Oct; 14(10):1777-84. PubMed ID: 11021753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
    Yalcintepe L; Frankel AE; Hogge DE
    Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.
    Florian S; Sonneck K; Hauswirth AW; Krauth MT; Schernthaner GH; Sperr WR; Valent P
    Leuk Lymphoma; 2006 Feb; 47(2):207-22. PubMed ID: 16321850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotyping and Target Expression Profiling of CD34
    Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
    Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In Vitro Identification and Characteristics of CD34
    Zhang YH; Yang L; Wang YZ; Kong Y; Zhu HH; Qin YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1289-1294. PubMed ID: 29070097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
    Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
    Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a leukemia-initiating stem cell in human mast cell leukemia.
    Eisenwort G; Sadovnik I; Schwaab J; Jawhar M; Keller A; Stefanzl G; Berger D; Blatt K; Hoermann G; Bilban M; Willmann M; Winding C; Sperr WR; Arock M; Rülicke T; Reiter A; Valent P
    Leukemia; 2019 Nov; 33(11):2673-2684. PubMed ID: 30953030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic characterization of malignant progenitor cells in patients with idiopathic myelofibrosis.
    Bao Y; Hu W; Guo Y; Yang W
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):146-154. PubMed ID: 30796884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.